Document Detail


The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction.
MedLine Citation:
PMID:  17390549     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Phosphodiesterase-5 (PDE-5) inhibitors are an effective therapy for the majority of men with erectile dysfunction (ED). However, many men with ED still report a suboptimal or partial response even after an adequate trial of oral PDE-5 therapy. Since ED is associated with impaired vascular function and both atorvastatin and quinapril have been previously shown to improve vascular function, we examined the effects of adjunctive treatment with these medications in men with vasculogenic ED who were suboptimal responders to 100 mg of sildenafil. Men with ED and suboptimal response to sildenafil were randomly assigned to 3 months of treatment with atorvastatin 40 mg (n = 12), quinapril 10 mg (n = 10), or placebo (n = 13), along with continued adjunctive sildenafil use. Measured variables included: International Index of Erectile Function (IIEF) questionnaire, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID) via nitroglycerin, penile Doppler blood flow, blood pressure (BP), lipids, and C-reactive protein (CRP). Compared to placebo, quinapril (p < 0.01) significantly improved symptoms of ED as measured by the IIEF-5 questionnaire. There was a trend toward a significant improvement in IIEF-5 with atorvastatin. Similarly, quinapril significantly improved the IIEF ED Domain (p < 0.05). Other peripheral and penile vascular parameters were unchanged with drug therapy as compared to placebo. In conclusion, treatment with quinapril, in combination with sildenafil, improved ED in men with suboptimal response to sildenafil alone. Atorvastatin demonstrated a trend toward improved ED in this group.
Authors:
Alan J Bank; Aaron S Kelly; Daniel R Kaiser; William W Crawford; Benjamin Waxman; Douglas A Schow; Kevin L Billups
Related Documents :
15334259 - Approximate entropy as a measure of complexity in sap flow temporal dynamics of two tro...
16937799 - The challenge of providing environmental flow rules to sustain river ecosystems.
689259 - Spatio-temporal relationships between protoplasmic streaming and contraction activities...
15811069 - Penile veins play a pivotal role in erection: the haemodynamic evidence.
18359059 - Emissions of otne (iso-e-super) - mass flows in sewage treatment plants.
3741289 - Effect of hyperbaric oxygen on the blood: cerebrospinal fluid transfer of tobramycin.
1266559 - Evaluation of a new spirometer based on a fluidistor technique.
8325179 - Superior mesenteric artery blood flow in celiac disease.
10207439 - Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Vascular medicine (London, England)     Volume:  11     ISSN:  1358-863X     ISO Abbreviation:  Vasc Med     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2007-03-29     Completed Date:  2007-04-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9610930     Medline TA:  Vasc Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  251-7     Citation Subset:  IM    
Affiliation:
St Paul Heart Clinic, St Paul, MN 55102, USA. abank@stphc.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Double-Blind Method
Drug Therapy, Combination
Heptanoic Acids / therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Impotence, Vasculogenic / drug therapy*
Male
Middle Aged
Phosphodiesterase Inhibitors / therapeutic use*
Piperazines / therapeutic use*
Purines / therapeutic use
Pyrroles / therapeutic use*
Questionnaires
Sulfones / therapeutic use*
Tetrahydroisoquinolines / therapeutic use*
Time Factors
Treatment Failure
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Pyrroles; 0/Sulfones; 0/Tetrahydroisoquinolines; 110862-48-1/atorvastatin; 139755-83-2/sildenafil; 82586-55-8/quinapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage ...
Next Document:  Acute lower limb ischemia due to thrombo-embolic arterial occlusions in two previously healthy men w...